Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof

• US 9,273,286 B2
• Filed: 11/11/2010
• Issued: 03/01/2016
• Est. Priority Date: 06/13/2010
• Status: Active Grant

• Current Assignee: Institute of Biophysics Chinese Academy of Sciences
• Original Assignee: Institute of Biophysics Chinese Academy of Sciences
• Inventors: Ma, Yue
• Primary Examiner(s): Ton, Thaian N
• Assistant Examiner(s): Moloye, Titilayo
• Application Number:
  US13/703,608
• Publication Number:
  US 20130209416A1
• Time in Patent Office: 1,937 Days
• US Class Current: 1/1
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/155 Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
• CPC Class Codes: C12N 2501/16 Activin; Inhibin; Mullerian inhibiting substance
• CPC Class Codes: C12N 2501/385 of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
• CPC Class Codes: C12N 2501/415 Wnt; Frizzeled
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells

Abstract

The present invention discloses novel compositions and methods for enhancing cardiac differentiation efficiency of stem cells or promoting ventricular and atrial cardiomyocytes formation from stem cells. The present invention also discloses the atrial and ventricular cardiomyocytes formed from the stem cells, and the uses of the cardiomyocytes for repairing cardiac injuries and screening for new medicaments for treating cardiac injuries.

Claims

1. An in vitro method for enhancing cardiac differentiation efficiency of a mammalian mesodermal cell, the method comprising:

contacting a mammalian mesodermal cell with a bone morphogenetic protein (BMP) antagonist and inhibiting retinoic acid signaling pathway in the mammalian mesodermal cell contacted with the BMP antagonist, thereby enhancing cardiac differentiation efficiency of the mammalian mesodermal cell.

2. The method of claim 1, wherein the mammalian mesodermal cell is differentiated from a human embryonic stem cell or a human induced pluripotent stem cell.

3. The method of claim 1, wherein the mammalian mesodermal cell is generated by contacting an undifferentiated mammalian stem cell with basic fibroblast growth factor (bFGF), BMP 4 and/or activin A.

4. The method of claim 1, wherein the BMP antagonist is a BMP4 antagonist, Noggin, Chordin, Tsg, a BMP soluble receptor, BMPRIA, BMPRIB or Dorsomorphin.

17. The method of claim 1, wherein the mammalian mesodermal cell is generated by contacting an undifferentiated mammalian stem cell with Wnt-3a, Bio, or CHIR99021.

5. An in vitro method for promoting ventricular cardiomyocyte formation from a mammalian mesodermal cell, the method comprising inhibiting retinoic acid signaling pathway in a mammalian mesodermal cell, thereby promoting ventricular cardiomyocyte formation from the mammalian mesodermal cell.

6. The method of claim 5, wherein the mammalian mesodermal cell is differentiated from a human embryonic stem cell or a human induced pluripotent stem cell.

7. The method of claim 5, wherein the mammalian mesodermal cell is generated by contacting an undifferentiated mammalian stem cell with basic fibroblast growth factor (bFGF), BMP 4 and/or activin A.

8. The method of claim 5, further comprising contacting the mammalian mesodermal cell with a BMP antagonist, wherein the BMP antagonist is a BMP4 antagonist, Noggin, Chordin, Tsg, a BMP soluble receptor, BMPRIA, BMPRIB or Dorsomorphin.

9. The method of claim 5, wherein the retinoic acid signaling pathway is inhibited by contacting the mammalian mesodermal cell with a pan-retinoic acid receptor antagonist, a retinoic acid antagonist, a retinoic acid receptor antagonist, or a retinoic X receptor antagonist.

18. The method of claim 5, wherein the mammalian mesodermal cell is generated by contacting an undifferentiated mammalian stem cell with Wnt-3a, Bio, or CHIR99021.

20. The method of claim 5, wherein the retinoic acid signaling pathway is inhibited by reducing vitamin A in a culture medium comprising the mammalian mesodermal cell.

21. The method of claim 5, wherein the retinoic acid signaling pathway is inhibited by depleting vitamin A in a culture medium comprising the mammalian mesodermal cell.

10. An in vitro method for promoting atrial cardiomyocyte formation from a mammalian mesodermal cell, the method comprising stimulating retinoic acid signaling pathway in a mammalian mesodermal cell, thereby promoting atrial cardiomyocyte formation from the mammalian mesodermal cell.

11. The method of claim 10, wherein the mammalian mesodermal cell is differentiated from a human embryonic stem cell or a human induced pluripotent stem cell.

12. The method of claim 10, wherein the mammalian mesodermal cell is generated by contacting an undifferentiated mammalian stem cell with basic fibroblast growth factor (bFGF), BMP 4 and/or activin A.

13. The method of claim 10, further comprising contacting the mammalian mesodermal cell with a BMP antagonist, wherein the BMP antagonist is a BMP4 antagonist, Noggin, Chordin, Tsg, a BMP soluble receptor, BMPRIA, BMPRIB or Dorsomorphin.

14. The method of claim 10, wherein the retinoic acid signaling pathway in the mammalian mesodermal cell is stimulated by contacting the cell with retinoic acid.

19. The method of claim 10, wherein the mammalian mesodermal cell is generated by contacting an undifferentiated mammalian stem cell with Wnt-3a, Bio, or CHIR99021.

22. The method of claim 10, wherein the retinoic acid signaling pathway in the mammalian mesodermal cell is stimulated by contacting the cell with vitamin A.

15. An in vitro method for generating a ventricular cardiomyocyte from a stem cell, the method comprising:

1) contacting a mammalian stem cell with bFGF and BMP4 to initiate stem cell differentiation;

2) contacting the mammalian stem cell treated with bFGF and BMP 4 with activin A to form a mesodermal cell;

3) contacting the mammalian mesodermal cell with Noggin for at least two days to enhance cardiac differentiation efficiency of the mammalian mesodermal cell;

4) inhibiting retinoic acid signaling pathway in the mammalian mesodermal cell of step

     3) for at least three days to promote ventricular cardiomyocyte formation and concurrently contacting the mammalian mesodermal cell of step

     3) with DKK1 for at least six days to differentiate the mammalian mesodermal cell into a ventricular cardiomyocyte.

16. An in vitro method for generating an atrial cardiomyocyte from a stem cell, the method comprising:

1) contacting a mammalian stem cell with bFGF and BMP4 to initiate stem cell differentiation;

2) contacting the mammalian stem cell treated with bFGF and BMP 4 with activin A to form a mesodermal cell;

3) contacting the mammalian mesodermal cell with Noggin for at least two days to enhance cardiac differentiation efficiency of the mammalian mesodermal cell;

4) stimulating retinoic acid signaling pathway in the mammalian mesodermal cell of step

     3) for at least three days to promote atrial cardiomyocyte formation and concurrently contacting the mammalian mesodermal cell of step

     3) with DKK1 for at least six days to differentiate the mammalian mesodermal cell into an atrial cardiomyocyte.

23. An in vitro method promoting atrial cardiomyocyte formation from a mammalian mesodermal cell, the method comprising not inhibiting retinoic acid signaling pathway in a mammalian mesodermal cell, thereby promoting atrial cardiomyocyte formation from the mammalian mesodermal cell.

24. An in vitro method for generating an atrial cardiomyocyte from a stem cell, the method comprising:

1) contacting a mammalian stem cell with bFGF and BMP4 to initiate stem cell differentiation;

2) contacting the mammalian stem cell treated with bFGF and BMP 4 with activin A to form a mesodermal cell;

3) contacting the mammalian mesodermal cell with Noggin for at least two days to enhance cardiac differentiation efficiency of the mammalian mesodermal cell;

4) not inhibiting retinoic acid signaling pathway in the mammalian mesodermal cell of step

     3) for at least three days to promote atrial cardiomyocyte formation and concurrently contacting the mammalian mesodermal cell of step

     3) with DKK1 for at least six days to differentiate the mammalian mesodermal cell into an atrial cardiomyocyte.